In this edition we dare to dream – fever dream, no less – about the future of the NHS. We go beyond the current chaos and ...

Sonoma Biotherapeutics has announced positive interim results from its ongoing phase 1 Regulate-RA trial evaluating ...

Alys Pharmaceuticals has announced the dosing of the first subject in its phase 1/1b trial of ALY-301, a first-in-class mast cell selective c-Kit inhibitor developed for the treatment of Cold ...

Domain Therapeutics has announced the first patients have been dosed in its phase 1/2 DOMISOL clinical trial of DT-7012, a ...

Qureight’s Vascul8 model has been validated in a peer-reviewed study marking a significant advance in the treatment of ...

Evotec SE has announced a $25m milestone payment from Bristol Myers Squibb, recognising scientific progress made within their ...

ENA Respiratory has raised US$22.4m (AU$34m) in Series B financing to support the phase 2 clinical development of its nasal ...

Nxera Pharma and its partner Cancer Research UK have presented encouraging results from the completed phase 1 portion of ...

The Global Fund has welcomed a £6 million joint investment from GSK and ViiV Healthcare to strengthen community-led responses ...

Incyte has announced promising new data from its phase 3b TRuE-AD4 trial of Opzelura (ruxolitinib cream) in adults with moderate atopic dermatitis (AD), revealing significant improvements in clinical ...

Janssen-Cilag International NV, part of Johnson & Johnson, has announced encouraging results from the phase 1b/2 OrigAMI-4 ...

ProImmune has announced the launch of its ProVE SL Self-Loading MHC Class I Monomers, a new reagent platform designed to enhance antigen-specific CD8+ T cell detection. The Oxford-based life science ...